These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 28817316)

  • 1. Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations.
    Ribeiro A; Lima S; Zampieri ME; Peinado M; Figueras A
    Expert Opin Drug Saf; 2017 Dec; 16(12):1329-1334. PubMed ID: 28817316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia-a restraint to the potentiality for signal detection.
    Plessis L; Gómez A; García N; Cereza G; Figueras A
    Eur J Clin Pharmacol; 2017 Jun; 73(6):751-758. PubMed ID: 28251276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quality of spontaneous adverse drug reaction reports from the pharmacovigilance centre in western China.
    Niu R; Xiang Y; Wu T; Zhang Z; Chen Y; Feng B
    Expert Opin Drug Saf; 2019 Jan; 18(1):51-58. PubMed ID: 30574811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of completeness of suspected adverse drug reaction reports submitted to the mexican national pharmacovigilance centre: a cross-sectional period-prevalence study.
    Sánchez-Sánchez B; Altagracia-Martínez M; Kravzov-Jinich J; Moreno-Bonett C; Vázquez-Moreno E; Martínez-Núñez JM
    Drug Saf; 2012 Oct; 35(10):837-44. PubMed ID: 22924896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Evaluation of Indian Consumers' Reporting of Suspected Adverse Drug Reactions with a Designated Reporting Form.
    Rehan HS; Sah R; Gupta A; Nagar P
    Curr Drug Saf; 2017; 12(1):51-56. PubMed ID: 27188794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does spontaneous adverse drug reactions' reporting differ between different reporters? A study in Toulouse Pharmacovigilance Centre.
    Nicol C; Moulis F; Bondon-Guitton E; Durrieu G; Montastruc JL; Bagheri H
    Therapie; 2019 Oct; 74(5):521-525. PubMed ID: 31029402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Causality assessment of adverse drug reaction reports using an expert-defined Bayesian network.
    Rodrigues PP; Ferreira-Santos D; Silva A; Polónia J; Ribeiro-Vaz I
    Artif Intell Med; 2018 Sep; 91():12-22. PubMed ID: 30077492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study.
    Durrieu G; Jacquot J; Mège M; Bondon-Guitton E; Rousseau V; Montastruc F; Montastruc JL
    Drug Saf; 2016 Dec; 39(12):1189-1195. PubMed ID: 27688025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantity is not enough: completeness of suspected adverse drug reaction reports in Spain-differences between regional pharmacovigilance centres and pharmaceutical industry.
    Fernandez-Fernandez C; Lázaro-Bengoa E; Fernández-Antón E; Quiroga-González L; Montero Corominas D
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1175-1181. PubMed ID: 32447435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The quality assessment of the Japanese Adverse Drug Event Report database using vigiGrade.
    Tsuchiya M; Obara T; Miyazaki M; Noda A; Takamura C; Mano N
    Int J Clin Pharm; 2020 Apr; 42(2):728-736. PubMed ID: 32020439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Looking back on 20 years of work at the Porto Pharmacovigilance Centre, Portugal].
    Ferreira-da-Silva R; Ribeiro-Vaz I; Silva AM; Marques J; Polónia JJ
    Cad Saude Publica; 2021; 37(10):e00304420. PubMed ID: 34644762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causality assessment in pharmacovigilance: The French method and its successive updates.
    Miremont-Salamé G; Théophile H; Haramburu F; Bégaud B
    Therapie; 2016 Apr; 71(2):179-86. PubMed ID: 27080836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the black triangle scheme and its online educational campaign on the quantity and quality of adverse drug event reporting in Australia: a time series analysis.
    Li R; Curtis K; Zaidi STR; Van C; Castelino R
    Expert Opin Drug Saf; 2020 Jun; 19(6):747-753. PubMed ID: 32207361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Completeness of pharmacovigilance reporting in general medicine in France.].
    Humbert X; Jacquot J; Alexandre J; Sassier M; Robin N; Pageot C; Kheloufi F; Joyau C; Coquerel A; Durrieu G; Fedrizzi S
    Sante Publique; 2019; Vol. 31(4):561-566. PubMed ID: 31959257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First experiences with a tool to measure the level of clinical information present in adverse drug reaction reports.
    Oosterhuis I; Rolfes L; Ekhart C; Muller-Hansma A; Härmark L
    Expert Opin Drug Saf; 2018 Feb; 17(2):111-115. PubMed ID: 29157026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Informativeness of patient initial reports of adverse drug reactions. Can it be improved by a pharmacovigilance centre?
    Kheloufi F; Default A; Rouby F; Laugier-Castellan D; Boyer M; Rodrigues B; Ponte-Astoul J; Jean-Pastor MJ; Blin O; Micallef J
    Eur J Clin Pharmacol; 2017 Aug; 73(8):1009-1018. PubMed ID: 28391408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reactions in Ghanaian children: review of reports from 2000 to 2012 in VigiBase.
    Cliff-Eribo KO; Choonara I; Dodoo A; Darko DM; Sammons H
    Expert Opin Drug Saf; 2015; 14(12):1827-33. PubMed ID: 26436964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suspected poor-quality medicines in Kenya: a retrospective descriptive study of medicine quality-related complaints reports in Kenya's pharmacovigilance database.
    Toroitich AM; Armitage R; Tanna S
    BMC Public Health; 2024 Sep; 24(1):2561. PubMed ID: 39300437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.